Familial hypercholesterolemia (FH) due to mutations in the low-density lipoprotein receptor (LDLR) gene exhibit severe, premature aortic calcification in a gene-dosage, age-dependent fashion. We sought to determine potential associations with mineral and skeletal indices.
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Vascular calcifications are frequently seen in advanced atherosclerosis (1 ) . These calcifications may also occur as a complication of metabolic disorders, especially disorders of calcium and phosphate commonly seen in end-stage renal failure, where secondary hyperparathyroidism is associated with calcium deposition in vascular tissue (2, 3 ) . Severe aortic and aortic valve calcifications were reported in homozygous familial hypercholesterolemia (FH) 3 (4 ) . More recently, we reported age-and gene dosage-dependent effects of mutations in the low-density lipoprotein receptor (LDLR) gene on aortic calcifications (5, 6 ) . LDLR residing on the surface of the liver is an essential protein in lipid metabolism. LDLR is located in clathrin-coated pits and is part of a protein complex that mediates receptor-mediated endocytosis of LDL particles, via the apolipoprotein (apo) B moiety. The LDL-LDLR complex is internalized together with other regulatory proteins, including proprotein convertase subtilisin/ kexin type 9 (PCSK9) (7 ) and the adapter protein autosomal recessive hypercholesterolemia (ARH) (8 ) .
Once the LDL particle enters the late endosomal pathways, the LDLR complex dissociates and LDLR is recycled back to the surface to clear more apo B-containing lipoproteins from the circulation. Mutations in the LDLR, apo B, PCSK9, or ARH genes cause FH, phenotypically characterized as markedly increased levels of cholesterol, cutaneous xanthomas and xanthelasmas, corneal arcus, premature atherosclerosis, and cardiovascular disease (coronary artery disease).
Recently, several studies have indicated an association of FH with premature calcification of the aorta. "Porcelain aorta" is a term used for severe ossification of the ascending aorta and is reported predominantly in the surgical literature describing the techniques required for aortic valve replacement and coronary bypass (4 ) . We undertook a systematic study of a Canadian cohort with homozygous FH optimally treated with antihyperlipidemic agents and extracorporeal LDL removal techniques to reach an acceptable LDL cholesterol concentration (50%-60% reduction), and we reported extensive calcifications of the aorta starting in the teenage years (5 ) . A similar pattern of vascular calcification was observed in FH heterozygotes (due to a null mutation of the LDLR), but was delayed by approximately 20 years in heterozygotes compared with homozygotes (6 ) . In controls without mutations at the LDLR gene, aortic calcifications were delayed until the sixth to seven decades of life. From the clinical standpoint, we have not previously observed such extensive arterial calcification as in FH. To examine potential alterations in calcium and/or skeletal homeostasis that might be associated with vascular calcifications in FH, we undertook a study of individuals with heterozygous FH due to a null mutation of the LDLR gene.
Materials and Methods

STUDY PARTICIPANTS
We selected heterozygote patients from our cohort of FH patients at the Preventive Cardiology/Lipid Clinic of the McGill University Health Centre (Montréal, Québec, Canada). All patients have the "FrenchCanadian" mutation of the LDLR gene, documented by PCR of genomic DNA. This mutation consists of a large copy number variant (approximately 15 kb) deletion of the promoter region, exon 1, and part of intron 1 of the LDLR gene. It results in a "null mutation" with no LDLR protein formed. No patients had endstage renal failure or were on hemodialysis, and none were taking medication that influences bone metabolism (e.g., vitamin D 3 , vitamin K, bisphosphonates, calcitonin, hormonal replacement, heparin, or anticonvulsants). None of the patients were heavy smokers, alcoholics, or drug abusers. All except three patients agreed to undergo computed tomography (CT) (without contrast material infusion) to quantify vascular calcifications as previously described (5 ) . Anthropometric and clinical data, time of diagnosis, therapy used, and duration of specific treatments were collected, and all relevant medical reports were reviewed. The protocol was reviewed and accepted by the Research Ethics Board of the McGill University Health Centre.
METHODS
Biochemical measurements.
We obtained serum and plasma samples from patients in the morning after an overnight fast and made an appropriate 24-h urine collection for measurement of creatinine and calcium by standard colorimetric assays. Intact immunoreactive parathyroid hormone (iPTH) was measured by a paramagnetic particle, chemiluminescent immunoassay (Access; Beckman Coulter), while total 25 hydroxyvi- Imaging. Patients underwent measurement of bone mineral density (BMD) by a dual-energy x-ray absorptiometry (DEXA) scan (GE-Lunar Prodigy) at the lumbar spine; hip and total BMD measurements were used for comparison. BMD values were then converted from lunar to hologic units using published conversion formulae (9 ) . The whole aorta calcium score (AoCS) was determined in Agatston units with use of a CT scan protocol and commercially available software as previously described (5 ).
Molecular testing. Mutational analysis was carried out using whole blood and a multiplex PCR, performed to detect the null Ͼ15-kb deletion known as the FrenchCanadian mutation (10 ) .
Statistical analysis. Descriptive statistics were used for discrete variables. The relationship between bone determinants was assessed with Spearman correlation coefficients. A paired t-test (two-tailed) was used to determine differences in discrete variables. A P value Ͻ0.05 was considered statistically significant.
Results
We examined 22 French-Canadian patients [15 men and 7 women, mean age (SD) 49 (14) years] with heterozygous FH attributable to the French-Canadian mutation of the LDLR gene. These patients were referred between years 1991 and 2007 and had a mean (SD) follow-up of 11 (4) years. Coronary artery disease was present in 11 of the patients, of whom three had myocardial infarction, two required angioplasty, and six needed surgical coronary revascularization (Table  1) . One patient was being treated for type 2 diabetes and another for hypothyroidism. Two patients (numbers 4 and 18) had asymptomatic hyperparathyroidism with serum iPTH concentrations of 10 and 17 pmol/L, respectively (upper reference limit, 7.5 pmol/L), but had serum calcium within the reference limits (11, 12 ) ( Table 2 ). These findings may have reflected vitamin D deficiency, since both patients had 25 hydroxyvitamin D Ͻ75 nmol/L. One patient (number 9) had a remote history of renal stones and two others (numbers 4 and 19) had incidental renal stones picked up by a CT scan; but serum and urine calcium were within reference limits in all three patients. The lipid profiles shown (Table 1) were taken from the patients' records before lipid-lowering therapy was initiated. As expected, the serum concentration of LDL cholesterol was Ͼ95th percentile for age-and sex-matched individuals and is typical for FH. The body mass index [mean (SD)] was 27 (6) kg/m 2 , and six patients had a body mass index Ͼ30 kg/m 2 . All patients were being treated with a statin at optimal dose, and 18 were also treated with ezetimibe, a selective cholesterol absorption inhibitor (Table 1) .
Parameters related to renal function and bone metabolism are shown in Table 2 . Mean serum creatinine (SD) was 83 (21) mol/L, and none of the patients had a creatinine concentration Ͼ130 mol/L. Estimated GFR (SD) using the MDRD formula was 84 (21) mL ⅐ min Ϫ1 ⅐ (1.73 m 2 ) Ϫ1 , and only two patients had a moderate decline in GFR (stage 3 chronic kidney disease). Mean serum calcium, albumin, magnesium, phosphorous, alkaline phosphatase, osteocalcin, CTX, CTX/osteocalcin ratio, and 24-h urinary excretion of calcium and creatinine were all within the reference interval (Table 2 ). Only two patients had a urinary fractional excretion of calcium Ͼ2.0. Mean 25 hydroxyvitamin D was 56 nmol/L, which was below the lower reference limit of 75 nmol/L generally accepted in North America but above the lower limit of 50 nmol/L often accepted in Europe. Mean 1,25 dihydroxyvitamin D was within the reference interval used in our hospital (23-113 pmol/L). Finally, mean (SD) calcium ϫ phosphorus product, an indicator of mineral crystallization risk in soft tissues, was calculated in our participants to be 2.
The mean femoral neck BMD was 0.990 (SD 0.140) g/cm 2 for men and 0.886 (0.099) g/cm 2 for women on a lunar scale (data not shown). The mean femoral neck BMD for men and women combined was near expected values from individuals matched for age, sex, and province, with a study sample mean estimated to be 0.002 (95% CI Ϫ0.043, 0.106) g/cm 2 lower than expected values, suggesting that femoral neck BMD was typical for that of the province of Quebec. The mean lumbar spine BMD was 1.196 (0.139) g/cm 2 for men and 1.149 (0.193) g/cm 2 for women on a lunar scale (data not shown). The mean lumbar spine BMD for men and women combined was higher than the expected values from Quebec residents matched for age and sex. Thus, the study sample mean was estimated to be 0.060 (95% CI Ϫ0.003, 0.122) g/cm 2 higher than expected values, most likely indicating that lumbar spine BMD measurement in these individuals could not be accurately measured because of the presence of substantial aortic calcification. For complete BMD measurements, see Supplemental Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/ vol56/issue10).
An extensive degree of calcification (AoCS Ͼ8000) was seen in 9 of 19 scanned patients resembling that seen in adult homozygote FH (Fig. 1) . Based on our previous reports in these patients, the level of abdominal aortic calcification observed in FH heterozygous patients in the present study was observed 30 years earlier than in non-FH patients (6 ) .
By Spearman correlation, we found no association between AoCS and T-score or absolute BMD (see Supplemental Table 2 in the online Data Supplement). The mean AoCS was 8074 (8526) ( Table 2 ) and correlated significantly with age (r ϭ 0.78, P ϭ 0.0001), similar to earlier studies (Awan et al. (5 ) : r ϭ 0.73, P ϭ 0.0001; Alrasadi et al. (6 ) : r ϭ 0.72, P ϭ 0.0016), but did not correlate with baseline LDL cholesterol (r ϭ 0.3 P ϭ 0.2). Interestingly, there was a negative correlation between estimated GFR (r ϭ Ϫ0.67, P ϭ 0.0019), serum osteocalcin (r ϭ Ϫ0.64, P ϭ 0.0034), urinary calcium (r ϭ Ϫ0.59, P ϭ 0.0085), and aortic calcium score (Fig.  2) . Weaker correlations were observed between AoCS and serum creatinine (r ϭ 0.48, P ϭ 0.0386) and serum calcium (r ϭ 0.48, P ϭ 0.0372).
However; we did not observe any significant correlation between AoCS and phosphorous, magnesium, calcium ϫ phosphorus product, iPTH, CTX, CTX/osteocalcin ratio, alkaline phosphatase, urinary creatinine, urinary fractional excretion of calcium, 25 hydroxyvitamin D, and 1,25 dihydroxyvitamin D. Similarly, correlations between spinal absolute BMD and the above-mentioned markers showed no significant correlation, except for a weak positive correlation with LDL cholesterol and a weak negative one with CTX. Finally, a weak correlation existed between serum creatinine, urinary creatinine, and femoral neck absolute BMD. For all correlations, see Supplemental Table 2 in the Data Supplement.
These data suggest that aortic calcium deposition in FH may be independent of BMD, vitamin D metabolism, Table 1 . Clinical lipid profile, lipid-lowering therapy, and cardiovascular disease in studied subjects. and serum calcium or phosphate concentrations. However, AoCS may be influenced by relatively low bone turnover, a decline in GFR, and urinary retention of calcium within the normal range of these parameters.
Discussion
We have previously reported an association between severe aortic calcification and FH and have shown an age-dependent, gene dosage effect of the LDLR gene on the AoCS (5, 6 ) . Although the progression of coronary atherosclerosis can be markedly decreased with statins and other lipid-lowering therapy combined with extracorporeal LDL filtration treatment, these treatments may not modify the process of aortic valve and aorta calcification. This is reflected by the need for aortic valve replacement for severe calcific aortic stenosis in homozygous FH patients despite long-term lipidlowering treatments (5 ). Patients with end-stage renal disease develop extensive and accelerated vascular calcifications as well, mostly in the medial layer (13 ) . This is in part attributable to increased expression of two genes induced by increased inorganic phosphate: the core-binding factor-1 gene, which is critical for osteoblast differentiation, and the gene encoding the bonespecific marker osteocalcin (2 ). In end-stage renal disease (stage 5 chronic kidney disease), the increased serum phosphorus and calcium/phosphorus product are thought to be the result of altered pathways of mineral metabolism characteristic of decreased renal function and secondary hyperparathyroidism. These factors and exogenous calcium and vitamin D supplementation were absent in our patients and therefore were unlikely to be instrumental. Many epidemiologic studies suggest a link between vascular calcification and cardiovascular disease events. The coronary calcium score is considered a surrogate marker of coronary atherosclerosis and is used by some to predict cardiovascular risk (14 ) . However, correlation between cardiovascular risk factors, arterial calcification, and bone tissue are inconsistent across studies. A few studies reported a direct relation between increased serum triglyceride levels and higher BMD (15, 16 ) , while an inverse relationship between cholesterol and BMD was shown by others (17 ) . A correlation between osteoporosis and cardiovascular disease has been made previously (16, 18 -20 ) , while other studies did not identify a relation between conventional cardiovascular risk factors and osteoporosis (21 ) . Interestingly, the magnitude of bone loss was related to aortic calcification in some studies (18, 20 -23 ) , and aortic calcification was attributed to cardiovascular risk factors in 30 other studies (24 ) .
Examination of BMD in the femoral neck and the lumbar spine in our studies showed that BMDs in these Quebec patients were no different from those in an age-matched Quebec population without FH. The slightly higher lumbar spine BMD is a known artifact in the DEXA scanning technique that occurs when bone is overlapped by mineralized tissue such as calcified aorta. It is likely, therefore, that bone loss is not the primary source of aortic calcium in these patients. Nevertheless, despite the lack of association of vascular calcification in FH with significant bone resorption or abnormalities of serum calcium or phosphorus, there was a strong negative correlation with serum osteocalcin. Osteocalcin is a bone matrix protein partly cleared by the kidney, and serum concentrations may increase as renal function declines. Nevertheless, although increased vascular calcifications were associated with reduced renal function, they also were associated with reduced serum osteocalcin, suggesting a biological basis for the association with vascular calcification that could not be explained by reduced renal function. Because serum osteocalcin is of skeletal origin and reflects the capacity of the osteoblast to synthesize bone matrix, the reduced concentrations of osteocalcin observed may indicate that abnormalities in the FH heterozygotes may impinge negatively on osteoblast function, despite the normal bone mineral density as assessed by DEXA. More sensitive techniques may be required to determine whether the vascular calcification in this dis- The plots illustrate the negative correlation between estimated GFR (r ϭ Ϫ0.67, P ϭ 0.0019), serum osteocalcin levels (r ϭ Ϫ0.64, P ϭ 0.0034), urinary calcium (r ϭ Ϫ0.59, P ϭ 0.0085), and aortic calcium score (AoCS).
order is partially attributable to decreased bone formation. Furthermore, the negative association between increased vascular calcification and urinary calcium observed suggests that ectopic calcium deposition may be related to a decrease filtered load of calcium, as reflected by the decreased calcium excretion. Finally, the reduced estimated GFR seen with increased vascular calcification may reflect renal vascular calcification and may facilitate reduced calcium excretion and increased deposition in blood vessels. It is also important to note that because the aortic calcification is predominantly subintimal in the aortic tissue rather than medial (5 ), the mechanisms of arterial calcification in FH are likely to differ from those seen in end-stage renal disease.
Based on clinical observation, we postulate a twohit theory of arterial calcification in FH: (i) subendothelial (intimal) injury due to the initiation of atherosclerosis and the uptake of oxidized LDL by macrophages leading to foam cell formation and an inflammatory reaction and (ii) deposition of calcium on matrix proteins in the intimal wall of genetically susceptible individuals. This would explain the agedependent increase in vascular calcification that is not altered by lipid-lowering therapy and duration of follow-up, reflecting length of disease and severity. Clinically, several trials to decrease the progression of aortic valve calcific stenosis using statins to lower LDL cholesterol have been neutral, indicating that there is no benefit of treatment and suggesting that lowering serum cholesterol to prevent aortic calcification may be futile (25 ) . Nevertheless, there is experimental support for the role of the LDLR in aortic calcification. Weiss et al. (26 ) reported echocardiographic evidence of aortic stenosis and abundant mineralization of aortic tissue in LDLR Ϫ/Ϫ mice expressing apo B100. A proposed unifying hypothesis for vascular calcification links atherosclerosis risk factors, genetic susceptibility, inflammatory mediators, and activation of the Wnt/Lrp5 and Runx2/Cbfa1 pathways and osteoblast differentiation (6 ) . Thus, the initiation of vascular calcification has been attributed to a change in phenotype of precursor cells into osteoblasts. Oxidative stress, low-grade inflammation, and angiogenesis in the adventitia induced by hyperglycemia (as in diabetics) and dyslipidemia may lead to the activation of the BMP2-Msx2 signaling cascade and activation of the Wnt cellular pathway and osteogenic differentiation (27 ) . Osteogenic cells and adventitial Msx2-expressing cells may arise from two mesenchymal aortic cell types. The first, described by Abedin et al. (28 ) , is a multipotent vascular mesenchymal progenitor that is recruited to form the mural calcifying vascular cells that are a macrovascular myofibroblast subtype related to microvascular pericytes that further function as osteoprogenitors, as has been demonstrated in vitro. The second are vascular smooth muscle cells that are undergoing osteo/chondrogenic transdifferentiation in response to hyperphosphatemia, which is an important trigger in patients with end-stage renal disease. Hyperphosphatemia can upregulate the osteo/chondrogenic transcription factor Runx2/Cbfa1 by vascular smooth muscle cells and enhance production of apoptotic cells and matrix vesicles, which nucleate vascular mineral deposition. However, since neither hyperglycemia nor hyperphosphatemia are factors in FH, these mechanisms may not be relevant in the present study. Furthermore, it remains unclear whether osteoblast differentiation occurs in the vessel wall in FH as it appears to in chronic renal failure, where alterations in the media of the vessel wall, rather than in the intima, seem to predominate. Further studies are therefore required to explore these issues.
In summary, based on this study, we conclude that disturbed mineral/skeletal homeostasis contributes, in part, to the pathophysiology of abnormal vascular calcifications observed in our patients but may not be the initiating event. The issue of calcium supplementation on cardiovascular risk remains unsettled. Data from Bolland et al. (29 ) show that the end points of major cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, and stroke) are significantly increased in women randomized to calcium supplementation for up to 5 years of follow-up. Akat et al. (30 ) reported an association between calcium metabolism and severe aortic valve stenosis in older individuals, suggesting that there are age-related alterations in calcium and bone homeostasis in calcific aortic stenosis. In our patients with accelerated atherosclerosis, we observed an association of increased vascular calcification with decreased urinary calcium excretion concomitant with modest reductions in renal function. Caution may be warranted in administering calcium supplements in an aging population where both an increased incidence of atherosclerosis and declining renal function coexist.
LIMITATIONS OF THE PRESENT STUDY
We carefully selected heterozygote FH patients on the basis of a null mutation to avoid confounding biases of having residual LDLR activity that may be present in other mutations of the LDLR gene. Other genetic causes of FH (mutations in the apo B, PCSK9, and ARH genes) were not examined. It would be especially interesting to examine patients with gain of function mutation in PCSK9 that decrease cell surface availability of the LDLR by decreasing its recycling. Thus, the LDLR protein is structurally intact in PCSK9 mutations, but not efficiently present at the plasma membrane. Our sample size is relatively small, in part, because we selected patients for a specific mutation of the LDLR gene and therefore we were unable to adjust for common variables such as age and sex. Finally, alkaline phosphatase and not bone-specific alkaline phosphatase was measured at our center. 
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